Instil Bio - TIL Enterprise Value-to-Revenue Multiple

Official company branding of Instil Bio Inc. (TIL)

Do the prospects of Instil Bio, Inc. (TIL) depend on clinical trial outcomes and cost control? A strong image in TIL therapy and the business value-to-annual revenue ratio confirm the asset's potential, where 0.00 represents the current metric level. Stable development is ensured by reliable cryogenic transportation of biomaterials, which guarantees uninterrupted supply chains.

TIL: Instil Bio EV/Sales Multiple 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Instil Bio (TIL)

- stock value and consensus price forecast:
Fundamental company valuation:Instil Bio, Inc. TIL
Product sample of instilbio.com

Identifying assets with a high margin of safety requires analyzing enterprise value, which subtracts net debt from the business value. This indicator measures the market valuation of a company relative to its sales, eliminating distortions caused by debt load. For Instil Bio, Inc. (TIL), the risks of a biotech logistics crisis could inflate asset values amid stagnating revenue. The trend of the EV-to-total-revenue multiple allows for the timely detection of overvaluation. Investors should interpret dips on this chart as a search for fundamental equilibrium.